Daily Guru Alerts
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
- Thursday, December 15, 2022
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
- Tuesday, December 6, 2022
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib.
- Dylan Jovine
- Monday, November 21, 2022
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
- Dylan Jovine
- Tuesday, October 4, 2022
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.
- Dylan Jovine
- Friday, January 13, 2023
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
- Thursday, December 15, 2022
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
- Tuesday, December 6, 2022
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib.
- Dylan Jovine
- Monday, November 21, 2022
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
- Dylan Jovine
- Tuesday, October 4, 2022
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.
deal of the month
Categories
A Warning for US Investors #shorts
Protecting Your Portfolio from the Rise of China #shorts
US Military LOSES in Simulated War Games Against China #shorts
Recent posts
Tags
Connect with Us
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.